It Seems Idexx Laboratories Inc (NASDAQ:IDXX) Will Go Up. Just Reported Less Shorted Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Logo

Investors sentiment decreased to 0.87 in 2019 Q2. Its down 0.39, from 1.26 in 2019Q1. It fall, as 35 investors sold IDEXX Laboratories, Inc. shares while 220 reduced holdings. 78 funds opened positions while 144 raised stakes. 70.76 million shares or 1.84% less from 72.09 million shares in 2019Q1 were reported.
Andra Ap owns 17,100 shares or 0.14% of their US portfolio. Everence Management Incorporated reported 2,060 shares. Victory Mgmt reported 16,934 shares. Capital Counsel New York stated it has 12.68% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Gemmer Asset Limited Liability Co accumulated 150 shares. Natl Pension reported 0.1% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Legacy Capital Partners Inc has 0.12% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Advisory Ser Networks Lc owns 317 shares. Rafferty Asset Mgmt Limited Co owns 8,368 shares. Pictet Asset Mgmt Limited reported 166,315 shares stake. Motley Fool Asset Mgmt Ltd Llc holds 0.04% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 1,401 shares. Cardinal Capital Management holds 1.33% in IDEXX Laboratories, Inc. (NASDAQ:IDXX) or 17,026 shares. Arrowstreet Capital Partnership accumulated 42,247 shares. Centurylink Mgmt has 0.66% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Winslow Evans & Crocker stated it has 1,000 shares.

Since August 6, 2019, it had 1 insider buy, and 0 insider sales for $99,904 activity.

The stock of Idexx Laboratories Inc (NASDAQ:IDXX) registered a decrease of 1.4% in short interest. IDXX’s total short interest was 1.10M shares in September as published by FINRA. Its down 1.4% from 1.12M shares, reported previously. With 430,800 shares average volume, it will take short sellers 3 days to cover their IDXX’s short positions. The short interest to Idexx Laboratories Inc’s float is 1.3%.

The stock decreased 2.05% or $5.55 during the last trading session, reaching $265.5. About 265,311 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 18.63% since September 13, 2018 and is uptrending. It has outperformed by 18.63% the S&P500.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, makes, and distributes services and products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company has market cap of $22.86 billion. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other divisions. It has a 57.36 P/E ratio. The firm provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage

Among 4 analysts covering Idexx Laboratories (NASDAQ:IDXX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Idexx Laboratories has $300 highest and $25500 lowest target. $276’s average target is 3.95% above currents $265.5 stock price. Idexx Laboratories had 10 analyst reports since March 26, 2019 according to SRatingsIntel. The stock has “Buy” rating by Bank of America on Friday, June 21. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Outperform” rating given on Friday, August 16 by Credit Suisse. Canaccord Genuity maintained it with “Buy” rating and $255 target in Tuesday, March 26 report.

More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: which released: “Should You Like IDEXX Laboratories, Inc.’s (NASDAQ:IDXX) High Return On Capital Employed? – Yahoo Finance” on May 14, 2019, also with their article: “IDEXX Laboratories Continues To Grow, But It’s Too Expensive To Buy – Seeking Alpha” published on May 07, 2019, published: “IDXX Crosses Above Average Analyst Target – Nasdaq” on August 28, 2019. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: and their article: “Morgan Stanley sees 23% upside in Galapagos in premarket analyst action – Seeking Alpha” published on September 09, 2019 as well as‘s news article titled: “IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance – Nasdaq” with publication date: August 01, 2019.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.